Although the rate of KRAS mutations was almost as twice as high in males with NSCLC compared to females (32 of 157 cases, 20.4% in males vs 11 of 97 cases; 11.3% in females), this difference was not found significant (p = 0.084). This evidence concerns the gene KRAS and non-small cell lung carcinoma.